Beam Therapeutics (BEAM) to Release Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Beam Therapeutics to post earnings of ($1.11) per share and revenue of $14.69 million for the quarter.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.16. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. During the same period in the previous year, the business earned $1.73 EPS. The business's quarterly revenue was down 90.5% on a year-over-year basis. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Stock Up 2.1 %

BEAM stock traded up $0.41 during trading on Friday, hitting $20.24. 1,777,936 shares of the company's stock traded hands, compared to its average volume of 1,394,612. The stock has a fifty day moving average price of $21.00 and a two-hundred day moving average price of $24.54. Beam Therapeutics has a 52 week low of $13.53 and a 52 week high of $35.25. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -11.50 and a beta of 2.35.

Analyst Upgrades and Downgrades

BEAM has been the subject of a number of research reports. Wedbush restated an "outperform" rating and issued a $57.00 target price on shares of Beam Therapeutics in a research note on Monday, March 10th. Sanford C. Bernstein raised shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 7th. Jones Trading upgraded shares of Beam Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 price objective on the stock in a research report on Monday, March 10th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research report on Monday, April 7th. Finally, Bank of America raised Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 price target on the stock in a report on Friday, March 28th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $49.45.

Insider Buying and Selling at Beam Therapeutics

In other Beam Therapeutics news, CEO John M. Evans sold 30,663 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $562,666.05. Following the transaction, the chief executive officer now directly owns 986,249 shares in the company, valued at approximately $18,097,669.15. This represents a 3.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Giuseppe Ciaramella sold 7,434 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $136,413.90. Following the completion of the transaction, the president now directly owns 190,216 shares in the company, valued at approximately $3,490,463.60. The trade was a 3.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,771 shares of company stock valued at $803,198 in the last quarter. Corporate insiders own 4.20% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.